United Therapeutics Corporation Announces Registration
Statement Declared Effective by SEC Silver Spring, Md. (PROTEXT)
Martine Rothblatt, Chairman and CEO of United Therapeutics Corporation (Nasdaq: UTHR), announced today that the registration statement for its initial public offering has been declared effective by the Securities and Exchange Commission. United Therapeutics has registered for sale to the public 4,500,000 shares of its Common Stock. The price to the public will be $12.00 per share. United Therapeutics expects trading in its Common Stock to begin today on the Nasdaq National Market. Deutsche Banc Alex. Brown is acting as lead manager of the underwriting. A.G. Edwards & Sons, Inc. and Vector Securities International, Inc. are acting as co-managers of the offering. A written prospectus may be obtained from Deutsche Banc Alex. Brown's Prospectus Department at One South Street, Baltimore, Maryland (410-727-1700). United Therapeutics develops pharmaceuticals to treat vascular diseases, including pulmonary hypertension and peripheral vascular disease, as well as selected other chronic conditions. ots Original Text Service: United Therapeutics Corporation Internet: http://www.newsaktuell.de Contact: Deutsche Banc Alex. Brown's Prospectus Department (USA) 410-727-1700, for United Therapeutics Corporation Web site: http://www.unitedtherapeutics.com
Materiály označené značkou Protext nejsou součástí zpravodajského servisu ČTK a nelze je publikovat pod její značkou. Jde o komerční sdělení zadavatele, který je ve zprávě označen a který za ně nese plnou odpovědnost.